Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) concerning whether a series of statements by Catalyst Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On February 17, 2016, Catalyst Pharmaceuticals announced that it has received a “Refusal to File” letter from the U.S. Food and Drug Administration regarding its New Drug Application for Firdapse. According to the "Refusal to File" letter, the Food and Drug Administration found that the application was not sufficiently complete and needs additional supporting information.   

On this news, NASDAQ: CPRX shares declined causing investor harm.

Based in Coral Gables, Florida, and founded in 2002 Catalyst Pharmaceuticals Inc is a development-stage biopharmaceutical company.

If you purchased shares of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) on or before February 17, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185